SUMMARY A regional quality control trial of folate assays is described. It is concluded that the trial is practical and useful in allowing inter-laboratory comparison of results, promoting discussion, and improving precision but it is impossible to assess accuracy. It was of no use in the comparison of assay methods, probably on account of the small number of laboratories participating.
Folate assays have received much criticism concerning accuracy, precision, inter-laboratory variance, and correlation with the clinical state of the patient.
Variations in technique have been explored, notably the introduction of a chloramphenicolresistant lactobacillus , but not necessarily with better results (Cooper, 1973) . It was, therefore, thought that this was a suitable assay for an inter-laboratory quality control scheme which might help the participants to judge their own performance. Four years ago we organised such a scheme in the former Manchester region.
Organisation of the regional scheme Initially, 19 laboratories in the region were invited to participate; only one laboratory declined. The laboratories were issued with numbers to preserve anonymity although it was accepted that we should be able to identify participants. More 
Results
There was a 770% return for the first 28 specimens.
One trial was unsatisfactory because of bacterial contamination of the sample. From one early trial insufficient returns were obtained for meaningful analysis.
The normal range quoted by the participants varied greatly. The lower limit lay between 1 and 5 ,ug/l and the upper between 5 and 25 ,ug/l. It was, therefore, necessary to assess the trial returns against the ranges quoted before comparing the returns with each other. No correlation between the individual results and the quoted normal range emerged. In six consecutive trials, nine laboratories, recording a lower limit of 3 ,ugl or less, gave a mean of 6 9 ug/l, whereas seven, with a lower limit of more than 3 p,g/l, gave a mean of 6-7 ,ug/l. The results in recovery experiments did not relate either to the quoted lower limit or to the extent of the ranges. Ofthe laboratories quoting specific limits, five with a range of less than (1961) , three the aseptic addition method of Herbert (1966) , and 14 a chloramphenicol-resistant organism . The cumulative MVI of those laboratories using the aseptic technique was the lowest (0 27) and that of those using the method of Waters and Mollin (1961) group.bmj.com on June 20, 2017 -Published by http://jcp.bmj.com/ Downloaded from too small but it may also be because some laboratories have not estimated their own normal ranges, suggested by their failure to record an upper limit.
It is difficult to assess improvements in accuracy and precision in an assay in which the true result is unknown. A good performance in the recovery experiments shows only that extrinsic folic acid is being measured accurately and not necessarily serum methyl folate. The steadily improving overall MVI shows that greater precision is being obtained throughout the region. Individual laboratories have been encouraged by seeing their own cumulative MVI improve.
It would be possible for a laboratory to produce results which differ from the mean by a constant amount in all trials; no improvement in its cumulative MVI would be seen but its service would be acceptable provided it had assessed its own normal range. We could not, however, identify any correlation between the results of the trials and the quoted normal ranges, suggesting that those laboratories with a high MVI were imprecise in their results.
As far as the organisation of the trial is concerned the main fault was the failure of laboratories to put their number on the questionnaire. The distribution of the relatively small number of specimens required in the trial has been practical, and we should like to increase the number of participants to 50 to give a balance between the work involved in the preparation ofspecimens and the amount of information obtained from the results. The collection, preparation, and dispensing of the samples, together with the statistical processing of the results, takes about 6 hours of technician time and 1I hours of clerical time for each trial. The cost of the trials, including postage and vials, is about £90-100 per annum. The volume of serum required for trials with 50 participants would be 200 ml. This would have to be doubled if betweenbatch precision tests were included, an improvement we intend to make. All specimens should be tested for HBsAg.
It has been difficult to know what sera to issue. It is desirable to test around the level of clinical significance but the SD of a mean at this level for few results is such that any below the mean is likely to be acceptable. However, by sending duplicate specimens with a known amount of folic acid added to one, we have been able to test at a low level and have a second, higher reading, in the range covered by the standard dilutions used in most laboratories. Not all radioligand assay techniques are, however, suitable for assay of folic acid. As well as liquid samples we have tried threefreeze-driedmaterials. Lyophylisation was time-consuming but produced a satisfactory sample. Two commercial preparations have been tried. A lyophylised horse serum (Wellcome) gave a low result in every laboratory with a mean of 1-4 ,ug/l despite the stated level of 6-1 ,ug/l. The other preparation, a lyophylised haemolysate from Armtrol, was satisfactory with a mean of 10-7 ,ug/l (stated level 9-8 ,ug/l) although this, and four other diluted haemolysates, gave greater variation in results than sera of comparable folate levels.
We believe that the most satisfactory scheme for quality control of folate assays for the country as a whole would be for two or three regions to group together, one centre correlating the results, and for there to be liaison between these centres.
We wish to thank our colleagues who put up with the initiation and continuation of this trial. 
